Rani Therapeutics Holdings Inc at Stifel Healthcare Conference Transcript
All right. We're going to get started. Thank you very much. Good morning. We're here for the Rani presentation.
I'm Annabel Samimy, biopharmaceutical analyst here at Stifel. And we have CEO, Talat Imran, and CFO, Svai Sanford. Rani is developing, hopefully, what will be the first successful injectable to oral technology for biologics.
So maybe I'll let you introduce the company for a few minutes first, and then we'll just launch into questions.
Absolutely. Annabel, thank you for the time. Thank you for giving us this opportunity and to Stifel as well. I'm going to go through these slides fairly quickly. We're going to make some forward-looking statements. As Annabel mentioned, my name is Talat Imran. I'm the CEO of Rani Therapeutics. I'm joined by Svai Sanford, our CFO.
Rani is a clinical-stage biotech. We're taking injectable biologics and turning them into pills. This is not a new idea. People have been trying to do this for the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |